Tamara Pilishvili

Tamara Pilishvili publications per year

Tamara Pilishvili publication distribution in Microbiology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Microbiology in 2026. The highlighted bar marks where Tamara Pilishvili sits on this spectrum.

Tamara Pilishvili D-index placement in Microbiology in 2026

The chart shows the D-index (discipline H-index) distribution of Microbiology scientists ranked by Research.com in 2026. The highlighted bar marks where Tamara Pilishvili sits on this spectrum.

Best Publications

• Decline in Invasive Pneumococcal Disease after the Introduction of Protein–Polysaccharide Conjugate Vaccine

  Cynthia G. Whitney;Monica M. Farley;James Hadler;Lee H. Harrison

  2790
  Citations

• Coronavirus Disease 2019 in Children - United States, February 12-April 2, 2020.

  Stephanie Bialek;Ryan Gierke;Michelle Hughes;Lucy A. McNamara

  1709
  Citations

• Sustained Reductions in Invasive Pneumococcal Disease in the Era of Conjugate Vaccine

  Tamara Pilishvili;Catherine Lexau;Monica M. Farley;Monica M. Farley;James Hadler

  1589
  Citations

• Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Updated Recommendations of the Advisory Committee on Immunization Practices

  Almea Matanock;Grace Lee;Ryan Gierke;Miwako Kobayashi

  662
  Citations

• Surveillance of Vaccination Coverage Among Adult Populations - United States, 2014.

  Unknown

  644
  Citations

• Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005.

  Matthew R Moore;Robert E Gertz;Robyn L Woodbury;Genevieve A Barkocy-Gallagher

  613
  Citations

• Surveillance of Vaccination Coverage among Adult Populations — United States, 2015

  Walter W. Williams;Peng-Jun Lu;Alissa O’Halloran;Alissa O’Halloran;David K. Kim

  484
  Citations

• Postvaccine Genetic Structure of Streptococcus pneumoniae Serotype 19A from Children in the United States

  Rekha Pai;Matthew R. Moore;Tamara Pilishvili;Robert E. Gertz

  418
  Citations

• Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2022

  Unknown

  328
  Citations

• Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021.

  Srinivas Nanduri;Tamara Pilishvili;Gordana Derado;Minn Minn Soe

  324
  Citations

• Intervals Between PCV13 and PPSV23 Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP).

  Miwako Kobayashi;Nancy M Bennett;Ryan Gierke;Olivia Almendares

  252
  Citations

• Noninfluenza vaccination coverage among adults - United States, 2012.

  Walter W. Williams;Peng-Jun Lu;Alissa O’Halloran;Carolyn B. Bridges

  250
  Citations

• Vaccination coverage among adults, excluding influenza vaccination - United States, 2013.

  Walter W Williams;Peng-Jun Lu;Alissa O'Halloran;Carolyn B Bridges

  237
  Citations

• Interim Recommendations from the Advisory Committee on Immunization Practices for the Use of Bivalent Booster Doses of COVID-19 Vaccines — United States, October 2022

  Unknown

  231
  Citations

• Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Children Aged 6–18 Years with Immunocompromising Conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP)

  Nancy M. Bennett;Tamara Pilishvili;Cynthia G. Whitney;Matthew Moore

  224
  Citations

• Interim Estimates of Vaccine Effectiveness of Pfizer-BioNTech and Moderna COVID-19 Vaccines Among Health Care Personnel - 33 U.S. Sites, January-March 2021.

  Tamara Pilishvili;Katherine E. Fleming-Dutra;Jennifer L. Farrar;Ryan Gierke

  208
  Citations

• Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection — Increasing Community Access to Testing Program, United States, September–November 2022

  Unknown

  185
  Citations

• Differential Effects of Pneumococcal Vaccines against Serotypes 6A and 6C

  In H. Park;Matthew R. Moore;John J. Treanor;Stephen I. Pelton

  185
  Citations

• Pneumococcal Vaccine for Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices, United States, 2023

  Unknown

  143
  Citations

• PCR-based quantitation and clonal diversity of the current prevalent invasive serogroup 6 pneumococcal serotype, 6C, in the United States in 1999 and 2006 to 2007.

  Maria da Gloria Carvalho;Fabiana C. Pimenta;Robert E. Gertz;Hari Har Joshi

  136
  Citations